Catalyst Pharmaceuticals Inc. (CPRX) witnessed a remarkable pre-market surge of 6.78% on November 7, 2024, driven by the company's outstanding financial performance and positive business updates for the third quarter of 2024.

The biopharmaceutical company reported record total revenues of $128.7 million for Q3 2024, a staggering 25.3% increase compared to the same period last year. This impressive growth was primarily fueled by the robust sales of its flagship product FIRDAPSE, a treatment for Lambert-Eaton myasthenic syndrome (LEMS), which saw net product revenues reaching $79.3 million, up 19.7% year-over-year.

Additionally, the successful launch of AGAMREE, Catalyst's newly introduced treatment for Duchenne muscular dystrophy, exceeded initial expectations, generating net product revenues of $15.0 million in its second full quarter of commercial availability. The company's stellar financial performance and positive business updates surpassed analyst expectations, driving investor optimism and fueling the pre-market stock price surge.